Vasopressin - Revision history

Danbot: Switch SMW query from broadtable to table format for better layout with TOC

2026-03-20T21:58:36Z

Switch SMW query from broadtable to table format for better layout with TOC

← Older revision		Revision as of 21:58, 20 March 2026
Line 63:		Line 63:
	\|?Has Route=Route		\|?Has Route=Route
	\|?Has Population=Population		\|?Has Population=Population
	\|format=~~broadtable~~		\|format=table
	\|headers=plain		\|headers=plain
	\|mainlabel=-		\|mainlabel=-

Danbot: Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

2026-03-20T17:24:48Z

Fix SMW query: replace link=subject with mainlabel=- to fix broken subobject fragment links

← Older revision		Revision as of 17:24, 20 March 2026
Line 65:		Line 65:
	\|format=broadtable		\|format=broadtable
	\|headers=plain		\|headers=plain
	\|~~link~~=~~subject~~		\|mainlabel=-
	\|sort=Has Indication		\|sort=Has Indication
	\|limit=50		\|limit=50

Danbot: Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

2026-03-20T16:42:56Z

Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)

@@ Line 52: / Line 52: @@
 **no difference in mortality when vasopressin was added as second line pressor compared to norepinephrine
 **subgroup analysis found that patients with less severe septic shock did better with vasopressin
 ==See Also==

Ostermayer at 16:02, 25 July 2025

2025-07-25T16:02:23Z

← Older revision		Revision as of 16:02, 25 July 2025
Line 1:		Line 1:
	==General==		==General==
	*Type: [[Vasopressors]]		*Type: [[Is DrugClass::Vasopressors]]
	*Dosage Forms:		*Dosage Forms:
	*Common Trade Names: Vasostrict (USA)		*Common Trade Names: Vasostrict (USA)

Elcatracho: /* General */

2023-12-28T23:20:31Z

General

← Older revision		Revision as of 23:20, 28 December 2023
Line 2:		Line 2:
	*Type: [[Vasopressors]]		*Type: [[Vasopressors]]
	*Dosage Forms:		*Dosage Forms:
	*Common Trade Names:		*Common Trade Names: Vasostrict (USA)

	==Adult Dosing==		==Adult Dosing==

Rossdonaldson1: /* See Also */

2022-12-07T22:45:56Z

Elcatracho: /* Notes */

2022-12-01T00:22:31Z

Notes

← Older revision		Revision as of 00:22, 1 December 2022
Line 46:		Line 46:
	*Adverse effects are dose-dependent		*Adverse effects are dose-dependent
	*Acts on V1 receptors leading to ↑vasoconstriction and		*Acts on V1 receptors leading to ↑vasoconstriction and
	↑sensitivity to catecholamines in patients with shock		*↑sensitivity to catecholamines in patients with shock
			*in contrast to catecholamine vasopressors (e.g. [[epinephrine]], [[norepinephrine]]), vasopressin does not lose efficacy at low pH
	===Indication===		===Indication===
	*Adjunct for septic shock VASST trial <ref> http://www.nejm.org/doi/full/10.1056/NEJMoa067373 </ref>		*Adjunct for septic shock VASST trial <ref> http://www.nejm.org/doi/full/10.1056/NEJMoa067373 </ref>

ClaireLewis: /* References */

2019-09-23T23:26:15Z

References

← Older revision		Revision as of 23:26, 23 September 2019
Line 59:		Line 59:

	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Critical Care]]

ClaireLewis: /* Special Populations */

2019-09-23T23:26:02Z

Special Populations

← Older revision		Revision as of 23:26, 23 September 2019
Line 14:		Line 14:

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C
	*Lactation:		*Lactation:
	*Renal Dosing		*Renal Dosing

Panosiaa: /* Pharmacology */

2017-07-13T23:42:59Z

Pharmacology

← Older revision		Revision as of 23:42, 13 July 2017
Line 6:		Line 6:
	==Adult Dosing==		==Adult Dosing==
	===Dosing===		===Dosing===
	*0.04 units/min		*0.01-0.04 units/min (typically 0.03 or 0.04 U/min)
	===Rate of Titration===		===Rate of Titration===
	*Fixed dose (do not titrate)		*Fixed dose (do not titrate)

	==Pediatric Dosing==		==Pediatric Dosing==
	0.0002–0.008 U/kg/min have been studied although no current consensus on dosage		0.0002–0.008 U/kg/min have been studied although no current consensus on dosage <ref>https://pdfs.semanticscholar.org/9f71/beefc10500d2d3a14d338d7b86b076729d3b.pdf </ref>

	<ref>https://pdfs.semanticscholar.org/9f71/beefc10500d2d3a14d338d7b86b076729d3b.pdf </ref>

	==Special Populations==		==Special Populations==
Line 35:		Line 33:

	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life: <20 minutes <ref> https://online.epocrates.com/u/1072232/vasopressin </ref>
	*Metabolism:		*Metabolism: liver, kidney extensively; CYP450: unknown
	*Excretion:		*Excretion: urine (5-6% unchanged)
	*Mechanism of Action:		*Mechanism of Action: "directly stimulates V1 and V2 receptors, resulting in vasoconstriction and antidiuresis" <ref> https://online.epocrates.com/u/1072232/vasopressin </ref>
	===Primary Receptor===		===Primary Receptor===
	*V1		*V1
	===Relative Effects===		===Relative Effects===
	*↑SVR		*↑SVR
	*↓HR		*↓HR

	==Notes==		==Notes==
Line 50:		Line 48:
	↑sensitivity to catecholamines in patients with shock		↑sensitivity to catecholamines in patients with shock
	===Indication===		===Indication===
	*Adjunct for septic shock		*Adjunct for septic shock VASST trial <ref> http://www.nejm.org/doi/full/10.1056/NEJMoa067373 </ref>
			**no difference in mortality when vasopressin was added as second line pressor compared to norepinephrine
			**subgroup analysis found that patients with less severe septic shock did better with vasopressin

	==See Also==		==See Also==
			http://www.atsjournals.org/doi/abs/10.1164/rccm.201006-0972CI?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#readcube-epdf

	==References==		==References==

← Older revision		Revision as of 22:45, 7 December 2022
Line 54:		Line 54:

	==See Also==		==See Also==
	http://www.atsjournals.org/doi/abs/10.1164/rccm.201006-0972CI?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#readcube-epdf		*http://www.atsjournals.org/doi/abs/10.1164/rccm.201006-0972CI?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed#readcube-epdf

	==References==		==References==